The Role of Pelvic Exenteration in Cervical Cancer: A Review of the Literature

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Feb 24

PMID 38398208

Authors

Ana Carla Franco Ubinha

Priscila Grecca Pedrao

Aline Cassia Tadini

Ronaldo Luis Schmidt

Marcelo Henrique dos Santos

Carlos Eduardo Mattos da Cunha Andrade

Adhemar Longatto Filho

Ricardo Dos Reis

Affiliations

Soon will be listed here.

Abstract

Pelvic exenteration represents a radical procedure aimed at achieving complete tumor resection with negative margins. Although it is the only therapeutic option for some cases of advanced tumors, it is associated with several perioperative complications. We believe that careful patient selection is related to better oncologic outcomes and lower complication rates. The objectives of this review are to identify the most current indications for this intervention, suggest criteria for case selection, evaluate recommendations for perioperative care, and review oncologic outcomes and potential associated complications. To this end, an analysis of English language articles in PubMed was performed, searching for topics such as the indication for pelvic exenteration for recurrent gynecologic neoplasms selection of oncologic cases, the impact of tumor size and extent on oncologic outcomes, preoperative and postoperative surgical management, surgical complications, and outcomes of overall survival and recurrence-free survival.

References

Baiocchi G, Guimaraes G, Rosa Oliveira R, Kumagai L, Faloppa C, Aguiar S . Prognostic factors in pelvic exenteration for gynecological malignancies. Eur J Surg Oncol. 2012; 38(10):948-54. DOI: 10.1016/j.ejso.2012.07.002. View

Xuan H, Myriam D, Charlotte N, Richard D, Anne-Sophie B, Olivier T . Pelvic exenteration by robotically-assisted laparoscopy: A feasibility series of 6 cases. Gynecol Oncol Rep. 2018; 25:56-59. PMC: 6038151. DOI: 10.1016/j.gore.2018.05.012. View

Lewandowska A, Szubert S, Koper K, Koper A, Cwynar G, Wicherek L . Analysis of long-term outcomes in 44 patients following pelvic exenteration due to cervical cancer. World J Surg Oncol. 2020; 18(1):234. PMC: 7469312. DOI: 10.1186/s12957-020-01997-3. View

Marnitz S, Kohler C, Muller M, Behrens K, Hasenbein K, Schneider A . Indications for primary and secondary exenterations in patients with cervical cancer. Gynecol Oncol. 2006; 103(3):1023-30. DOI: 10.1016/j.ygyno.2006.06.027. View

Goldberg G, Sukumvanich P, Einstein M, Smith H, Anderson P, Fields A . Total pelvic exenteration: the Albert Einstein College of Medicine/Montefiore Medical Center Experience (1987 to 2003). Gynecol Oncol. 2006; 101(2):261-8. DOI: 10.1016/j.ygyno.2005.10.011. View

McLean K, Zhang W, Dunsmoor-Su R, Shah C, Gray H, Swensen R . Pelvic exenteration in the age of modern chemoradiation. Gynecol Oncol. 2011; 121(1):131-4. DOI: 10.1016/j.ygyno.2010.11.044. View

Tortorella L, Casarin J, Mara K, Weaver A, Multinu F, Glaser G . Prediction of short-term surgical complications in women undergoing pelvic exenteration for gynecological malignancies. Gynecol Oncol. 2018; 152(1):151-156. DOI: 10.1016/j.ygyno.2018.10.036. View

Gheorghe M, Cozlea A, Kiss S, Stanca M, Capilna M, Bacalbasa N . Primary pelvic exenteration: Our experience with 23 patients from a single institution. Exp Ther Med. 2021; 22(4):1060. PMC: 8353644. DOI: 10.3892/etm.2021.10494. View

de Gregorio N, De Gregorio A, Ebner F, Friedl T, Huober J, Hefty R . Pelvic exenteration as ultimate ratio for gynecologic cancers: single-center analyses of 37 cases. Arch Gynecol Obstet. 2019; 300(1):161-168. DOI: 10.1007/s00404-019-05154-4. View

10.

Smith B, Jones E, Kitano M, Gleisner A, Lyell N, Cheng G . Influence of tumor size on outcomes following pelvic exenteration. Gynecol Oncol. 2017; 147(2):345-350. DOI: 10.1016/j.ygyno.2017.08.014. View

11.

Matsuo K, Matsuzaki S, Mandelbaum R, Kanao H, Chang E, Klar M . Utilization and perioperative outcome of minimally invasive pelvic exenteration in gynecologic malignancies: A national study in the United States. Gynecol Oncol. 2021; 161(1):39-45. DOI: 10.1016/j.ygyno.2020.12.036. View

12.

Million R, Rutledge F, FLETCHER G . Stage IV carcinoma of the cervix with bladder invasion. Am J Obstet Gynecol. 1972; 113(2):239-46. DOI: 10.1016/0002-9378(72)90773-9. View

13.

Park J, Choi H, Jeong S, Chung J, Park J, Park S . The role of pelvic exenteration and reconstruction for treatment of advanced or recurrent gynecologic malignancies: Analysis of risk factors predicting recurrence and survival. J Surg Oncol. 2007; 96(7):560-8. DOI: 10.1002/jso.20847. View

14.

Jurado M, Alcazar J, Baixauli J, Hernandez-Lizoain J . Low colorectal anastomosis after pelvic exenteration for gynecologic malignancies: risk factors analysis for leakage. Int J Gynecol Cancer. 2011; 21(2):397-402. DOI: 10.1097/IGC.0b013e31820b2df7. View

15.

Ter Glane L, Hegele A, Wagner U, Boekhoff J . Pelvic exenteration for recurrent or advanced gynecologic malignancies - Analysis of outcome and complications. Gynecol Oncol Rep. 2021; 36:100757. PMC: 8059060. DOI: 10.1016/j.gore.2021.100757. View

16.

Baiocchi G, Guimaraes G, Faloppa C, Kumagai L, Oliveira R, Dirlei Begnami M . Does histologic type correlate to outcome after pelvic exenteration for cervical and vaginal cancer?. Ann Surg Oncol. 2012; 20(5):1694-700. DOI: 10.1245/s10434-012-2768-6. View

17.

SHINGLETON H, Bell M, Fremgen A, Chmiel J, Russell A, Jones W . Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma of the cervix?. Cancer. 1995; 76(10 Suppl):1948-55. DOI: 10.1002/1097-0142(19951115)76:10+<1948::aid-cncr2820761311>3.0.co;2-t. View

18.

Urh A, Soliman P, Schmeler K, Westin S, Frumovitz M, Nick A . Postoperative outcomes after continent versus incontinent urinary diversion at the time of pelvic exenteration for gynecologic malignancies. Gynecol Oncol. 2013; 129(3):580-5. PMC: 3935607. DOI: 10.1016/j.ygyno.2013.02.024. View

19.

Puntambekar S, Rajamanickam S, Agarwal G, Joshi S, Rayate N, Deshmukh A . Laparoscopic posterior exenteration in advanced gynecologic malignant disease. J Minim Invasive Gynecol. 2010; 18(1):59-63. DOI: 10.1016/j.jmig.2010.09.003. View

20.

Grigsby P, Perez C, Kuske R, CAMEL H, Kao M, Galakatos A . Adenocarcinoma of the uterine cervix: lack of evidence for a poor prognosis. Radiother Oncol. 1988; 12(4):289-96. DOI: 10.1016/0167-8140(88)90018-7. View